Please login to the form below

Not currently logged in
Email:
Password:

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

Astellas Claire ThomDr Claire Thom has left her role at Takeda to join rival Japanese pharma company Astellas as senior VP of global oncology development.

Dr Thom was most recently senior VP portfolio management, drug development management and strategic business operations at Millennium, the oncology-focused subsidiary of Takeda.

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

At Millennium Dr Thom will have worked on Velcade, a drug co-developed with Johnson & Johnson (J&J) that is used in blood cancer.

"We're thrilled that Claire is joining our experienced oncology team at Astellas," said Dr Sef Kurstjens, chief medical officer of Astellas.

“We believe that her unique background and varied experience, along with her approach to leadership and management will support our mission to become a global category leader in oncology."

Prior to joining Millennium, Dr Thom served for several years at Takeda itself, including holding responsibility for the oversight and implementation of the global therapeutic area strategies for the company's oncology, urology and gynaecology franchises.

14th August 2013

From: Research, Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Biosimilars and beyond: innovating for improved patient outcomes
How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...